Cowen's Phil Nadeau says that its latest physician survey suggests sales of Regeneron's (REGN...


Cowen's Phil Nadeau says that its latest physician survey suggests sales of Regeneron's (REGN 8.9%) big revenue driver, Eylea, may be slowing. Measuring the uptake of the company's treatment for a leading cause of blindness in the elderly, the number of patients on the drug grew 22% from March to May, compared to 155% growth from January to March. Based on this level of deceleration, Cowen thinks the stock may be rich at these levels.
From other sites
Comments (1)
  • boyle99
    , contributor
    Comment (1) | Send Message
     
    Plus 122% on a small base is probably less than plus 22% on a much larger base.
    Peter Boyle - long time REGN shareholder
    1 Jun 2012, 04:28 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs